<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38468304</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6963</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>BMC health services research</Title><ISOAbbreviation>BMC Health Serv Res</ISOAbbreviation></Journal><ArticleTitle>COVID-19-associated costs and mortality in Germany: an incidence-based analysis from a payer's perspective.</ArticleTitle><Pagination><StartPage>321</StartPage><MedlinePgn>321</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">321</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12913-024-10838-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aims to estimate average COVID-19-associated healthcare costs per capita in Germany from a payer perspective. In addition, insights into COVID-19-associated mortality should be gained.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">For this purpose, a retrospective longitudinal analysis using health insurance claims data was performed. Patients affected by COVID-19 in Q1/2021 (investigation group (IG)) were compared to a matched non-COVID-19 control group (CG) (1:1 propensity score matching (PSM)). Mean values of healthcare costs in 2020 and 2021 were computed for both groups and then separated by age and by development of Post-COVID-19 Syndrome (PCS). Group differences were examined using Mann-Whitney U test (&#x3b1;&#x2009;=&#x2009;0.05). Difference-in-Differences approach (DiD) was used to estimate average cost effects of COVID-19 in 2021. Concerning mortality, the number of deaths in 2021 was compared between IG and CG using &#x3c7;<sup>2</sup> test of independence.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 8,014 insurants were included (n&#x2009;=&#x2009;4,007 per group; n&#x2009;=&#x2009;536 per group examining PCS patients only). Total healthcare costs varied a lot in the sample, were comparable between IG and CG in 2020, but were significantly higher in the IG in 2021 (DiD estimate&#x2009;=&#x2009;&#x20ac; 1,063 (in total); &#x20ac; 3,242 (PCS group)). This was more pronounced in the older age groups. High hospital costs of a minority of patients were the most influential driver of COVID-19-associated healthcare costs. Mortality was more than doubled in the IG (tripled in patients aged&#x2009;&#x2265;&#x2009;60).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">COVID-19 is associated with significantly increased healthcare costs and mortality, especially in older age groups. The additional development of PCS further increases the costs of COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brandt</LastName><ForeName>Florian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-4947-1770</Identifier><AffiliationInfo><Affiliation>IKK S&#xfc;dwest, Europaallee 3-4, Saarbr&#xfc;cken, 66113, Germany. florian.brandt@ikk-sw.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simone</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>IKK S&#xfc;dwest, Europaallee 3-4, Saarbr&#xfc;cken, 66113, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loth</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>IKK S&#xfc;dwest, Europaallee 3-4, Saarbr&#xfc;cken, 66113, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>IKK S&#xfc;dwest, Europaallee 3-4, Saarbr&#xfc;cken, 66113, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Health Serv Res</MedlineTA><NlmUniqueID>101088677</NlmUniqueID><ISSNLinking>1472-6963</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cost of illness</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Matched-pair</Keyword><Keyword MajorTopicYN="N">Population-based</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">Secondary data analysis</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>12</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38468304</ArticleId><ArticleId IdType="pmc">PMC10926608</ArticleId><ArticleId IdType="doi">10.1186/s12913-024-10838-y</ArticleId><ArticleId IdType="pii">10.1186/s12913-024-10838-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bonotti M, Zech ST. The Human, Economic, Social, and Political Costs of COVID-19. In: Bonotti M, Zech ST, editors. Recovering Civility during COVID-19. Singapore: Palgrave Macmillan; 2021. pp. 1&#x2013;39.</Citation></Reference><Reference><Citation>ifo Institute. Coronavirus Pandemic Caused EUR 330 Billion in Economic Losses for Germany. Munich; 2022. Available at: https://www.ifo.de/en/press-release/2022-02-17/coronavirus-pandemic-caused-eur-330-billion-economic-losses-germany. Accessed 02 Feb 2023.</Citation></Reference><Reference><Citation>Busse R, Schrey&#xf6;gg J, editors. Management im Gesundheitswesen. 5th ed. Berlin/Heidelberg: Springer; 2022. p. 1&#x2013;10. 10.1007/978-3-662-64176-7.</Citation></Reference><Reference><Citation>GKV Spitzenverband [Central Federal Association of the Statutory Health Insurance Companies]. Zahlen und Grafiken &#x2013; Kennzahlen der gesetzlichen Krankenversicherung &#x2013; Versicherte je System in Prozent [Figures and graphics &#x2013; key figures of the statutory health insurance &#x2013; insured per system in percent]. Berlin; 2022. Available at: https://www.gkv-spitzenverband.de/service/zahlen_und_grafiken/zahlen_und_grafiken.jsp. Accessed 03 Feb 2023.</Citation></Reference><Reference><Citation>Richards F, Kodjamanova K, Chen X, et al. Economic Burden of COVID-19: A Systematic Review. Clinicoecon Outcomes Res. 2022;14:293&#x2013;307. doi: 10.2147/CEOR.S338225.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CEOR.S338225</ArticleId><ArticleId IdType="pmc">PMC9060810</ArticleId><ArticleId IdType="pubmed">35509962</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeck J, Jakobs F, Kron A, et al. A cost of illness study of COVID&#x2011;19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic &#x201c;frst wave&#x201d; in a German tertiary care hospital. Infection. 2022;50:191&#x2013;201. doi: 10.1007/s15010-021-01685-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01685-8</ArticleId><ArticleId IdType="pmc">PMC8371942</ArticleId><ArticleId IdType="pubmed">34406606</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandjour A. How many intensive care beds are justifiable for hospital pandemic preparedness? A cost-effectiveness analysis for COVID-19 in Germany. Appl Health Econ Health Policy. 2021;19:181&#x2013;190. doi: 10.1007/s40258-020-00632-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40258-020-00632-2</ArticleId><ArticleId IdType="pmc">PMC7801567</ArticleId><ArticleId IdType="pubmed">33433853</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8:853&#x2013;862. doi: 10.1016/S2213-2600(20)30316-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30316-7</ArticleId><ArticleId IdType="pmc">PMC7386882</ArticleId><ArticleId IdType="pubmed">32735842</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiell A, Gerard K, Donaldson C. Cost of illness studies: An aid to decision-making? Health Policy. 1987;8:317&#x2013;323. doi: 10.1016/0168-8510(87)90007-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-8510(87)90007-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom BS, Bruno DJ, Maman DY, et al. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics. 2001;19:207&#x2013;213. doi: 10.2165/00019053-200119020-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-200119020-00007</ArticleId><ArticleId IdType="pubmed">11284384</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaya FT, Mullins CD, Wong W. Incidence versus prevalence modeling in pharmacoeconomics. Expert Rev Pharmacoeconomics Outcomes Res. 2002;2:435&#x2013;442. doi: 10.1586/14737167.2.5.435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737167.2.5.435</ArticleId><ArticleId IdType="pubmed">19807467</ArticleId></ArticleIdList></Reference><Reference><Citation>GKV Spitzenverband [Central Federal Association of the Statutory Health Insurance Companies]. GKV-Kennzahlen &#x2013; Ausgaben f&#xfc;r einzelne Leistungsbereiche der GKV 2021 in Prozent [GKV key figures &#x2013; expenditure for individual service areas of the GKV 2021 in percent]. Berlin; 2022. Available at: https://www.gkv-spitzenverband.de/service/zahlen_und_grafiken/gkv_kennzahlen/gkv_kennzahlen.jsp. Accessed 03 Feb 2023.</Citation></Reference><Reference><Citation>Tran V, Porcher R, Pane I, Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun. 2022;13:1812. doi: 10.1038/s41467-022-29513-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29513-z</ArticleId><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert Koch Institute (RKI). Bericht zu Virusvarianten von SARS-CoV-2 in Deutschland [Report on virus variants of SARS-CoV-2 in Germany]. Berlin; 12 Mai 2021. Available at: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/DESH/Bericht_VOC_2021-05-12.pdf?__blob=publicationFile. Accessed 03 Feb 2023.</Citation></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41&#x2013;55. doi: 10.1093/biomet/70.1.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/70.1.41</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265&#x2013;2281. doi: 10.1002/(sici)1097-0258(19981015)17:19&lt;2265::aid-sim918&gt;3.0.co;2-b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1097-0258(19981015)17:19&lt;2265::aid-sim918&gt;3.0.co;2-b</ArticleId><ArticleId IdType="pubmed">9802183</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399&#x2013;424. doi: 10.1080/00273171.2011.568786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00273171.2011.568786</ArticleId><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Gesundheitsberichterstattung des Bundes [Federal health reporting]. H&#xe4;ufigste Diagnosen in Prozent der Behandlungsf&#xe4;lle in Arztpraxen in Nordrhein (Rang und Anteil). Gliederungsmerkmale: Jahre, Nordrhein, Geschlecht, ICD10, Arztgruppe [Most common diagnoses as a percentage of treatment cases in medical practices in North Rhine (rank and share). Structural features: years, North Rhine-Westphalia, gender, ICD10, physician group]. Berlin; 27 July 2016. Available at: https://www.gbe-bund.de/gbe/pkg_isgbe5.prc_menu_olap?p_uid=gast&amp;p_aid=22070480&amp;p_sprache=D&amp;p_help=0&amp;p_indnr=638&amp;p_indsp=&amp;p_ityp=H&amp;p_fid=. Accessed 03 Feb 2023.</Citation></Reference><Reference><Citation>STandardisierte BerichtsROutine f&#xfc;r Sekund&#xe4;rdaten Analysen (STROSA) &#x2013; ein konsentierter Berichtsstandard f&#xfc;r Deutschland, Version 2 [A Consensus German Reporting Standard for Secondary Data Analyses, Version 2 (STROSA-STandardisierte BerichtsROutine f&#xfc;r Sekund&#xe4;rdatenAnalysen)]. Gesundheitswesen. 2016;78(Suppl. 1):e145&#x2013;e160. 10.1055/s-0042-108647</Citation><ArticleIdList><ArticleId IdType="pubmed">27428525</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B, Larson C, Hammond TC, et al. A Review of Persistent Post-COVID Syndrome (PPCS) Clin Rev Allergy Immunol. 2023;64:66&#x2013;74. doi: 10.1007/s12016-021-08848-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-021-08848-3</ArticleId><ArticleId IdType="pmc">PMC7896544</ArticleId><ArticleId IdType="pubmed">33609255</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya J-M, Rojas M, Salinas ML, et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021;20:102947. doi: 10.1016/j.autrev.2021.102947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102947</ArticleId><ArticleId IdType="pmc">PMC8428988</ArticleId><ArticleId IdType="pubmed">34509649</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Statist. 1947;18:50&#x2013;60. doi: 10.1214/aoms/1177730491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/aoms/1177730491</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bulletin. 1945;1:80&#x2013;83. doi: 10.2307/3001968.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/3001968</ArticleId></ArticleIdList></Reference><Reference><Citation>Gertler PJ, Martinez S, Premand P, et al. Impact Evaluation in Practice. 2. Washington, DC: Inter-American Development Bank and World Bank; 2016.</Citation></Reference><Reference><Citation>Wing C, Simon K, Bello-Gomez RA. Designing Difference in Difference Studies: Best Practices for Public Health Policy Research. Annu Rev Public Health. 2018;39:453&#x2013;469. doi: 10.1146/annurev-publhealth-040617-013507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-publhealth-040617-013507</ArticleId><ArticleId IdType="pubmed">29328877</ArticleId></ArticleIdList></Reference><Reference><Citation>Starke K, Reissig D, Petereit-Haack G, et al. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Global Health. 2021;6(12):e006434. doi: 10.1136/bmjgh-2021-006434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-006434</ArticleId><ArticleId IdType="pmc">PMC8678541</ArticleId><ArticleId IdType="pubmed">34916273</ArticleId></ArticleIdList></Reference><Reference><Citation>VassarStats: Website for Statistical Computation. Available at: http://vassarstats.net/. Accessed 06 Feb 2023.</Citation></Reference><Reference><Citation>Nalbandian A, Desai AD, Wan EY. Post-COVID-19 Condition. Annu Rev Med. 2023;74:55&#x2013;64. doi: 10.1146/annurev-med-043021-030635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-043021-030635</ArticleId><ArticleId IdType="pubmed">35914765</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2021;75:e13746. doi: 10.1111/ijcp.13746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.13746</ArticleId><ArticleId IdType="pmc">PMC7536922</ArticleId><ArticleId IdType="pubmed">32991035</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemeinsamer Bundesausschuss [Federal Joint Committee]. WATCH &#x2013; Mobile wohnortnahe Versorgung zur Steuerung der sektor&#xfc;bergreifenden Therapie bei Post-COVID-19 in Th&#xfc;ringen [WATCH &#x2013; Mobile care close to home to control cross-sector therapy for post-COVID-19 in Thuringia]. Available at: https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/watch-mobile-wohnortnahe-versorgung-zur-steuerung-der-sektoruebergreifenden-therapie-bei-post-covid-19-in-thueringen.574. Accessed 05 Oct 2023.</Citation></Reference><Reference><Citation>Bartsch SM, Ferguson MC, McKinnell JA, et al. The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States. Health Aff (Millwood) 2020;39:927&#x2013;935. doi: 10.1377/hlthaff.2020.00426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2020.00426</ArticleId><ArticleId IdType="pmc">PMC11027994</ArticleId><ArticleId IdType="pubmed">32324428</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM. The Costs of Long COVID. JAMA Health Forum. 2022;3(5):e221809. doi: 10.1001/jamahealthforum.2022.1809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2022.1809</ArticleId><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>OECD &amp; European Observatory on Health Systems and Policies. Country Health Profiles. Available at: https://health.ec.europa.eu/state-health-eu/country-health-profiles_en. Accessed 05 Oct 2023.</Citation></Reference><Reference><Citation>OECD &amp; European Observatory on Health Systems and Policies . Germany: Country Health Profile 2021, State of Health in the EU. Paris: OECD Publishing, Brussels: European Observatory on Health Systems and Policies; 2021.</Citation></Reference><Reference><Citation>Mehraeen E, Karimi A, Barzegary A, et al. Predictors of mortality in patients with COVID-19&#x2013;a systematic review. Eur J Integr Med. 2020;40:101226. doi: 10.1016/j.eujim.2020.101226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eujim.2020.101226</ArticleId><ArticleId IdType="pmc">PMC7568488</ArticleId><ArticleId IdType="pubmed">33101547</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SJ, Jung SI. Age-Related Morbidity and Mortality among Patients with COVID-19. Infect Chemother. 2020;52(2):154&#x2013;164. doi: 10.3947/ic.2020.52.2.154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3947/ic.2020.52.2.154</ArticleId><ArticleId IdType="pmc">PMC7335648</ArticleId><ArticleId IdType="pubmed">32537961</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi C, Wang L, Ye J, et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):663. doi: 10.1186/s12879-021-06369-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06369-0</ArticleId><ArticleId IdType="pmc">PMC8264491</ArticleId><ArticleId IdType="pubmed">34238232</ArticleId></ArticleIdList></Reference><Reference><Citation>Gesundheitsberichterstattung des Bundes [Federal health reporting]. Todesursachenstatistik [Cause of death statistics]. Available at: https://www.gbe-bund.de/gbe/pkg_isgbe5.prc_menu_olap?p_uid=gast&amp;p_aid=92356495&amp;p_sprache=D&amp;p_help=0&amp;p_indnr=6&amp;p_indsp=658&amp;p_ityp=H&amp;p_fid=. Accessed 05 Oct 2023.</Citation></Reference><Reference><Citation>BARMER Institut f&#xfc;r Gesundheitssystemforschung (bifg) [BARMER Institute for Health Systems Research]. Morbidit&#xe4;ts- und Sozialatlas [Morbidity and Social Atlas]. Available at: https://www.bifg.de/atlas. Accessed 05 Oct. 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>